Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - Yahoo News Canada

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target  Yahoo News Canada

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - Yahoo News Canada

Click here to get full coverage on $DNLI stock is up 2% today. Here's what we see in our data. - Nasdaq

$DNLI stock is up 2% today. Here's what we see in our data.  Nasdaq

$DNLI stock is up 2% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

When (DNLI) Moves Investors should Listen  news.stocktradersdaily.com

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

Click here to get full coverage on What analysts say about DNLI stock - High-impact investment strategies - Jammu Links News

What analysts say about DNLI stock - High-impact investment strategies  Jammu Links News

What analysts say about DNLI stock - High-impact investment strategies - Jammu Links News

Click here to get full coverage on Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan

Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care  Stock Titan

Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan

Click here to get full coverage on Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution  simplywall.st

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Click here to get full coverage on Is DNLI a good long term investment - High-yield growth strategies - Jammu Links News

Is DNLI a good long term investment - High-yield growth strategies  Jammu Links News

Is DNLI a good long term investment - High-yield growth strategies - Jammu Links News

Click here to get full coverage on 12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

12 Oversold NASDAQ Stocks to Buy Now  Insider Monkey

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Click here to get full coverage on DNLI July 18th Options Begin Trading - Nasdaq

DNLI July 18th Options Begin Trading  Nasdaq

DNLI July 18th Options Begin Trading - Nasdaq

Click here to get full coverage on Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review  Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

Click here to get full coverage on DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review  Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

Click here to get full coverage on Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan

Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage  Stock Titan

Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan

Click here to get full coverage on Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?  Insider Monkey

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey

Click here to get full coverage on Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?  Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up  Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

Click here to get full coverage on Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Yahoo Finance

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?  Yahoo Finance

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - Stock Titan

Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025  Stock Titan

Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - Stock Titan

Click here to get full coverage on Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - Stock Titan

Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference  Stock Titan

Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - Stock Titan

Click here to get full coverage on Denali Gains 26.6% in a Year: How Should You Play the Stock? - Yahoo Finance

Denali Gains 26.6% in a Year: How Should You Play the Stock?  Yahoo Finance

Denali Gains 26.6% in a Year: How Should You Play the Stock? - Yahoo Finance

Click here to get full coverage on DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - Yahoo Finance

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation  Yahoo Finance

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - Yahoo Finance

Click here to get full coverage on Denali Therapeutics’ FDA Priority Review for New Therapy - TipRanks

Denali Therapeutics’ FDA Priority Review for New Therapy  TipRanks

Denali Therapeutics’ FDA Priority Review for New Therapy - TipRanks

Click here to get full coverage on Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI)  Seeking Alpha

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewswire

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome  GlobeNewswire

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewswire

Click here to get full coverage on Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Yahoo Finance

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases  Yahoo Finance

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Yahoo Finance

Click here to get full coverage on Denali Therapeutics Continues To Have Plenty Of Moving Parts (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics Continues To Have Plenty Of Moving Parts (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics Continues To Have Plenty Of Moving Parts (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights  GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Click here to get full coverage on BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $28 - 富途牛牛

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $28  富途牛牛

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $28 - 富途牛牛

Click here to get full coverage on Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology  Seeking Alpha

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights  GlobeNewswire

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Click here to get full coverage on 5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - Yahoo Finance

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates  Yahoo Finance

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - Yahoo Finance

Click here to get full coverage on Denali Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Denali Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90  Investor's Business Daily

Denali Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Click here to get full coverage on Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewswire

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa  GlobeNewswire

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewswire

Click here to get full coverage on Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Denali Therapeutics Reports 2024 Financial Results and Progress  TipRanks

Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Click here to get full coverage on Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - Zacks Investment Research

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus  Zacks Investment Research

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - Zacks Investment Research

Click here to get full coverage on Denali looks to scale new heights in quest for treatment for rare genetic disorder - San Francisco Business Times - The Business Journals

Denali looks to scale new heights in quest for treatment for rare genetic disorder - San Francisco Business Times  The Business Journals

Denali looks to scale new heights in quest for treatment for rare genetic disorder - San Francisco Business Times - The Business Journals

Click here to get full coverage on Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Yahoo Finance

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected  Yahoo Finance

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Yahoo Finance

Click here to get full coverage on Sanofi and Denali drop Phase II oditrasertib trial - The Pharma Letter

Sanofi and Denali drop Phase II oditrasertib trial  The Pharma Letter

Sanofi and Denali drop Phase II oditrasertib trial - The Pharma Letter

Click here to get full coverage on Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - Yahoo Finance

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights  Yahoo Finance

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - Yahoo Finance

Click here to get full coverage on Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire

Denali Therapeutics Announces Upcoming Presentations on  GlobeNewswire

Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire

Click here to get full coverage on Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer - PR Newswire

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer  PR Newswire

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer - PR Newswire

Click here to get full coverage on Flagship Pioneering Debuts Enabling Technologies Initiative - PR Newswire

Flagship Pioneering Debuts Enabling Technologies Initiative  PR Newswire

Flagship Pioneering Debuts Enabling Technologies Initiative - PR Newswire

Click here to get full coverage on Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine - PR Newswire

Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine  PR Newswire

Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine - PR Newswire

Click here to get full coverage on Denali's (DNLI) Pipeline Progresses Despite Stiff Competition - Nasdaq

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition  Nasdaq

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition - Nasdaq

Click here to get full coverage on Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner - PR Newswire

Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner  PR Newswire

Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner - PR Newswire

Click here to get full coverage on Denali Therapeutics (DNLI) - Zacks Investment Research

Denali Therapeutics (DNLI)  Zacks Investment Research

Denali Therapeutics (DNLI) - Zacks Investment Research

Click here to get full coverage on Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics - PR Newswire

Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics  PR Newswire

Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics - PR Newswire

Click here to get full coverage on Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative - PR Newswire

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative  PR Newswire

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative - PR Newswire

Click here to get full coverage on Denali Therapeutics (DNLI) Stock Price, News & Analysis - MarketBeat

Denali Therapeutics (DNLI) Stock Price, News & Analysis  MarketBeat

Denali Therapeutics (DNLI) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on 3 Longevity Stocks to Buy for Anti-Aging Breakthroughs - InvestorPlace

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs  InvestorPlace

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs - InvestorPlace

Click here to get full coverage on Bearish: Analysts Just Cut Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue and EPS estimates - Yahoo Home

Bearish: Analysts Just Cut Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue and EPS estimates  Yahoo Home

Bearish: Analysts Just Cut Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue and EPS estimates - Yahoo Home

Click here to get full coverage on Denali Therapeutics Announces $500 million Private Placement Equity Financing - GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing  GlobeNewswire

Denali Therapeutics Inc (DNLI)

Price Chart

Key Statistics

Technicals

About DNLI

Latest News

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - Yahoo News Canada

$DNLI stock is up 2% today. Here's what we see in our data. - Nasdaq

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

Advanced Charts

Top Gainers

Top Losers